Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
about
Oral deferiprone for iron chelation in people with thalassaemiaIron homeostasis in host defence and inflammationSafety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channelsEffect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosisTreatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf areaHealth-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran.Clinical Impact and Cellular Mechanisms of Iron Overload-Associated Bone Loss.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Deferasirox for managing iron overload in people with thalassaemia.How we manage iron overload in sickle cell patients.The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System.The Assessment of Skin Color and Iron Levels in Pediatric Patients with β-Thalassemia Major Using a Visual Skin Color Chart.Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma.Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.Speciation in Metal Toxicity and Metal-Based Therapeutics.Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cellsDeferasirox: Over a Decade of Experience in Thalassemia
P2860
Q24200309-AEABF31D-795E-4008-A70A-0CA50B2852E8Q28083811-FB9F44B9-5A18-4EE0-AEDE-202A3808C08DQ33407282-A2CBC2E5-D41D-40F5-83FC-9B5E241F802FQ34649067-EA3F078A-22D5-452B-9DCB-65C4148F2DBAQ34692473-1F196C07-2E0A-49B2-AB68-B21BF7DEEFEAQ35803018-AF4133A6-9249-40CB-9BF5-5BFCCEE04116Q36891845-1A85F4EC-7A40-49B2-8294-FE38BF49C2A7Q37359617-E0B355C7-9CF7-4551-BE42-797E52B817C7Q37477990-FF87F951-4C1E-40CA-895A-B556171E6175Q37653861-0904C651-6F56-4EFE-866A-DA7AAEAB0C1AQ38540491-823A1B1C-60B8-4D41-AB84-1114E580EBB9Q38624033-52DCF684-FE9F-47AF-926E-E0E41BE29DE7Q39179372-9E50E91A-10F5-42B9-AFCB-875967C45D46Q39260564-82C12DE9-9920-4A9C-9F08-A0C537EBA338Q39271327-A46D22C5-5EAA-4F5C-A37B-45B9EB033123Q40171505-C3C74C0E-0D9D-4D5D-8284-A5D824C9DFB5Q41952792-CC866DCE-773D-4932-9247-C63910988876Q46103118-D042701F-A577-4B39-A895-FD03E4CE9725Q46737692-B7FEC113-3A13-4756-ACFE-1C1AE0CD0739Q53995645-65E59892-B208-4835-B09E-71780DCED1F4Q56974269-71CAC5E3-542E-44DB-B4CF-D226846887D0Q58701123-7D9F2406-CCFD-4A7C-8B28-57BA30082A03
P2860
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Iron chelation therapy in thal ...... on randomized clinical trials.
@en
Iron chelation therapy in thal ...... on randomized clinical trials.
@nl
type
label
Iron chelation therapy in thal ...... on randomized clinical trials.
@en
Iron chelation therapy in thal ...... on randomized clinical trials.
@nl
prefLabel
Iron chelation therapy in thal ...... on randomized clinical trials.
@en
Iron chelation therapy in thal ...... on randomized clinical trials.
@nl
P2093
P50
P1476
Iron chelation therapy in thal ...... on randomized clinical trials.
@en
P2093
Adriana Ceci
Aldo Filosa
Angela Iacono
Angela Vitrano
Antonis Kattamis
Filippo Cassarà
Giuseppina Aloj
Luciano Prossomariti
Paolo Cianciulli
P304
P356
10.1016/J.BCMD.2011.07.002
P577
2011-08-16T00:00:00Z